Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample

in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

23/06/2026

𝐀𝐫𝐞 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐠𝐚𝐩𝐬 𝐥𝐢𝐦𝐢𝐭𝐢𝐧𝐠 𝐲𝐨𝐮𝐫 𝐝𝐫𝐮𝐠’𝐬 𝐫𝐞𝐚𝐜𝐡 𝐢𝐧 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲?
Our Idylla™ Platform can help close these gaps.

Idylla™ is a fully automated molecular testing platform with 3 hours TAT, few invalid results, suitable for any lab and a global reach.

Partnering with Biocartis means we develop Idylla™ tests that identify the right biomarkers in your drug’s target population — and ensure those tests are accessible wherever your drug needs to reach, closing multiple diagnostic gaps along the way.

Let’s find your entry point → [email protected]

18/06/2026

𝐈𝐝𝐲𝐥𝐥𝐚™. 𝐁𝐚𝐜𝐤𝐞𝐝 𝐛𝐲 𝟑𝟎𝟎+ 𝐩𝐞𝐞𝐫-𝐫𝐞𝐯𝐢𝐞𝐰𝐞𝐝 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬
The Idylla™ Platform isn’t just fast, it's highly accurate and scientifically proven. With over 300 peer-reviewed publications, Idylla™ demonstrates real-world impact in molecular biomarker testing.

𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 👉 https://www.biocartis.com/en/meet-idylla/publications?utm_source=facebook&utm_medium=social&utm_campaign=publications

17/06/2026

𝗝𝗢𝗜𝗡 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: 𝗖𝗥𝗖 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟲: 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘄, 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘅𝘁? 𝗔𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝗶𝘀𝘁'𝘀 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗼𝗻 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗧𝗲𝘀𝘁𝗶𝗻𝗴
📅 Thursday 25 June, 13:00 (CEST)
🎤 Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds)
📍 Online, registration required

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- The key changes in ESMO mCRC guidelines
- The role of dual IHC/molecular testing for immunotherapy eligibility
- The emerging testing strategies in early-stage disease

👉 𝗦𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄: https://lnkd.in/eCACjXx3
Can’t join live? By registering, you will get access to the recording afterwards.

16/06/2026

June marks 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, highlighting the growing role of immune-based approaches, such as immune checkpoint inhibitors, across multiple cancer types 📈

In colorectal cancer (CRC), MSI-H tumors arise from deficient DNA mismatch repair, leading to 𝐡𝐢𝐠𝐡 𝐥𝐞𝐯𝐞𝐥𝐬 𝐨𝐟 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐜𝐡𝐚𝐧𝐠𝐞𝐬 and the formation of neoantigens that can 𝐭𝐫𝐢𝐠𝐠𝐞𝐫 𝐚𝐧 𝐢𝐦𝐦𝐮𝐧𝐞 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞. 𝐓𝐮𝐦𝐨𝐫𝐬 𝐜𝐚𝐧 𝐞𝐯𝐚𝐝𝐞 this response by activating immune checkpoint pathways such as PD-1 / PD-L1 and CTLA-4, which reduce immune activity against cancer cells…

💡 Immune checkpoint inhibitors, including 𝐎𝐏𝐃𝐈𝐕𝐎® (𝐧𝐢𝐯𝐨𝐥𝐮𝐦𝐚𝐛) 𝐚𝐧𝐝 𝐘𝐄𝐑𝐕𝐎𝐘® (𝐢𝐩𝐢𝐥𝐢𝐦𝐮𝐦𝐚𝐛), block these pathways and restore immune activity. This allows the immune system to recognize and eliminate tumor cells, 𝐡𝐞𝐥𝐩𝐢𝐧𝐠 𝐭𝐨 𝐬𝐥𝐨𝐰 𝐨𝐫 𝐬𝐭𝐨𝐩 𝐭𝐮𝐦𝐨𝐫 𝐠𝐫𝐨𝐰𝐭𝐡 𝐚𝐧𝐝 𝐬𝐩𝐫𝐞𝐚𝐝.
💪 Reliable MSI testing is therefore essential to identify patients who may benefit from immunotherapy.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐂𝐃𝐱 𝐌𝐒𝐈 𝐓𝐞𝐬𝐭* 👉 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-cdx-msi-test?utm_source=facebook&utm_medium=social&utm_campaign=idylla-cdx-msi-test

*𝘊𝘌-𝘮𝘢𝘳𝘬𝘦𝘥 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘪𝘯 𝘤𝘰𝘮𝘱𝘭𝘪𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘌𝘜 𝘐𝘝𝘋 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯 2017/746 (𝘐𝘝𝘋𝘙) 𝘢𝘯𝘥 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘪𝘯 𝘮𝘢𝘯𝘺 𝘰𝘵𝘩𝘦𝘳 𝘤𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴. 𝐴𝑝𝑝𝑟𝑜𝑣𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑈𝑆 𝑢𝑛𝑑𝑒𝑟 P250005. 𝘖𝘗𝘋𝘐𝘝𝘖® 𝘢𝘯𝘥 𝘠𝘌𝘙𝘝𝘖𝘠® 𝘢𝘳𝘦 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘵𝘳𝘢𝘥𝘦𝘮𝘢𝘳𝘬𝘴 𝘰𝘧 𝘉𝘳𝘪𝘴𝘵𝘰𝘭-𝘔𝘺𝘦𝘳𝘴 𝘚𝘲𝘶𝘪𝘣𝘣 𝘊𝘰𝘮𝘱𝘢𝘯𝘺.

11/06/2026

Molecular biomarker results in ONLY 3 HOURS!
💡 THINK IDYLLA™

Today, Biocartis offers tests and assays enabling rapid biomarker results in lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer samples.

More information 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=meet-idylla

09/06/2026

📢 𝗣𝗥𝗘𝗦𝗦 𝗡𝗘𝗪𝗦: 𝗕𝗶𝗼𝗰𝗮𝗿𝘁𝗶𝘀 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗖𝗶𝘁𝘆 𝗼𝗳 𝗛𝗼𝗽𝗲 𝘁𝗼 𝗘𝘅𝗽𝗹𝗼𝗿𝗲 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗥𝗮𝗽𝗶𝗱 𝗚𝗲𝗻𝗲 𝗦𝗶𝗴𝗻𝗮𝘁𝘂𝗿𝗲 𝗧𝗲𝘀𝘁 𝗳𝗼𝗿 𝗘𝗮𝗿𝗹𝘆 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗣𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗖𝗮𝗻𝗰𝗲𝗿
We're excited to announce that we have entered into an agreement with City of Hope to explore the development of a 𝗿𝗮𝗽𝗶𝗱, 𝗯𝗹𝗼𝗼𝗱-𝗯𝗮𝘀𝗲𝗱, 𝘀𝗮𝗺𝗽𝗹𝗲-𝘁𝗼-𝗮𝗻𝘀𝘄𝗲𝗿 𝗴𝗲𝗻𝗲 𝘀𝗶𝗴𝗻𝗮𝘁𝘂𝗿𝗲 𝘁𝗲𝘀𝘁 𝗳𝗼𝗿 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗽𝗮𝗻𝗰𝗿𝗲𝗮𝘁𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿. Under the agreement, Biocartis has secured an option to license key patents and related know-how from City of Hope* to accelerate test development on the Idylla™ Platform.

👉 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: https://lnkd.in/ettYgXtg

𝘛𝘩𝘦 𝘵𝘦𝘴𝘵 𝘪𝘯 𝘪𝘴 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘶𝘴𝘦.
* 𝘜𝘯𝘥𝘦𝘳 𝘵𝘩𝘦 𝘵𝘦𝘳𝘮𝘴 𝘰𝘧 𝘵𝘩𝘦 𝘰𝘱𝘵𝘪𝘰𝘯 𝘢𝘨𝘳𝘦𝘦𝘮𝘦𝘯𝘵, 𝘊𝘪𝘵𝘺 𝘰𝘧 𝘏𝘰𝘱𝘦 𝘪𝘴 𝘦𝘯𝘵𝘪𝘵𝘭𝘦𝘥 𝘵𝘰 𝘢𝘯 𝘰𝘱𝘵𝘪𝘰𝘯 𝘧𝘦𝘦 𝘱𝘢𝘺𝘮𝘦𝘯𝘵.

09/06/2026

🌸☀️𝐒𝐩𝐫𝐢𝐧𝐠 𝐜𝐥𝐞𝐚𝐧𝐢𝐧𝐠 𝐢𝐬𝐧’𝐭 𝐣𝐮𝐬𝐭 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐡𝐨𝐦𝐞, 𝐲𝐨𝐮𝐫 𝐥𝐚𝐛 𝐝𝐞𝐬𝐞𝐫𝐯𝐞𝐬 𝐚 𝐫𝐞𝐟𝐫𝐞𝐬𝐡 𝐭𝐨𝐨!

Is your lab still dealing with cluttered workstations and complex workflows?
Declutter your lab. Simplify your workflow. THINK IDYLLA™:
✅ < 3 minutes hands-on time
✅ compact & fully automated system
✅ molecular biomarker results in only 3 hours

🔗 Get more info now: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=meet-idylla

07/06/2026

🎗️ Today, on National Cancer Survivors Day®, we celebrate the strength, resilience, and stories of millions who have faced cancer — and have overcome it.

At Biocartis, we are proud to support this journey with Idylla™, our fully automated platform that delivers fast and accurate molecular insights — empowering informed and personalized treatment decisions at the heart of cancer survival.
🔬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐡𝐨𝐰 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐢𝐬 𝐡𝐞𝐥𝐩𝐢𝐧𝐠 𝐚𝐝𝐯𝐚𝐧𝐜𝐞 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲: https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

04/06/2026

𝗝𝗢𝗜𝗡 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: 𝗖𝗥𝗖 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝟮𝟬𝟮𝟲: 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘄, 𝗪𝗵𝗮𝘁'𝘀 𝗡𝗲𝘅𝘁? 𝗔𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝗶𝘀𝘁'𝘀 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗼𝗻 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗧𝗲𝘀𝘁𝗶𝗻𝗴
📅 Thursday 25 June, 13:00 (CEST)
🎤 Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds)
📍 Online, registration required

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
- The key changes in ESMO mCRC guidelines
- The role of dual IHC/molecular testing for immunotherapy eligibility
- The emerging testing strategies in early-stage disease

👉 𝗦𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄: https://register.gotowebinar.com/register/7831863561846158940
Can’t join live? By registering, you will get access to the recording afterwards.

02/06/2026

𝟏 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦. 𝟗𝟓+ 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬. 𝐂𝐨𝐮𝐧𝐭𝐥𝐞𝐬𝐬 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝.
The Idylla™ Platform empowers pathologists and oncologists worldwide with fast, reliable molecular biomarker testing. Every day, it helps them make confident, data-driven decisions.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://www.biocartis.com/en/meet-idylla/idylla-platform?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.